Vaxart’s investigational recombinant vaccine is based on its VAAST platform. Credit: Psychonaught.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Emergent BioSolutions has agreed to provide molecule-to-market contract development and manufacturing (CDMO) services for Vaxart’s oral vaccine candidate against Covid-19 coronavirus infection.

Emergent will immediately begin development services for the investigational recombinant vaccine, based on Vaxart’s VAAST platform.

After Vaxart’s election, Emergent will generate clinical material for a Phase I clinical trial to conducted in the second half of this year.

Emergent BioSolutions CDMO business unit head Syed Husain said: “We look forward to applying our broad molecule-to-market services, including our ability to work with a multitude of delivery systems, execute under expedited timelines, and meet Vaxart’s potential need for future scalability and large-scale capacity for commercial quantities.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Emergent will deliver development services from its location in Baltimore, Maryland, US. The company will produce drug substance at its Bayview facility in Baltimore.

The facility holds the capacity to manufacture several millions of doses of vaccine per year.  It can produce at a clinical scale and also scale up to commercial volumes.

Vaxart CEO Wouter Latour said: “We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign, and Emergent is a great partner to help in this endeavour.”

Earlier this month, Emergent began efforts to develop two plasma-derived product candidates to treat and prevent Covid-19.

Emergent also agreed to provide CDMO services for Novavax’s Covid-19 experimental vaccine candidate.